94E.F Zura Bio Limited
- Market cap
- EUR 121M
- P/E
- -
- P/B
- 0.64x
- ROE
- -57.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 94E.F undervalued?
Graham numberThe Graham number of Zura Bio Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zura Bio Limited fundamental analysis
No fundamental analysis for Zura Bio Limited yet.
Zura Bio Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targ…
Full company profileZura Bio Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zura Bio Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.09M | -2.68M | -62.6M | -55.2M | -75.2M | -111M |
| EBITDA | 8.42M | -27.3M | -60.6M | -55.2M | -75.2M | -111M |
| Net Income | 8.42M | 3.55M | -60.4M | -52.4M | -68.7M | -102M |
| EPS | 0.49 | 0.21 | -1.83 | -0.70 | -0.93 | -1.06 |
| Balance Sheet | ||||||
| Total Assets | 4.72M | 142M | 101M | 180M | 114M | 195M |
| Total Liabilities | 39.0K | 14.8M | 21.3M | 19.5M | 12.4M | 17.0M |
| Shareholders' Equity | 4.68M | -32.1M | 59.3M | 147M | 102M | 178M |
| Cash & Short-term Investments | 4.72M | 13.8K | 99.8M | 176M | 109M | 188M |
| Total Debt | - | 356K | - | - | - | - |
| Cash Flow | ||||||
| Operating Cash Flow | -1.10M | -1.07M | -15.1M | -28.1M | -64.8M | -79.1M |
| Capital Expenditure | 0.00 | 12.0M | 8.00M | 5.08M | 113K | 97.3K |
| Free Cash Flow | -1.10M | -13.1M | -23.1M | -33.2M | -64.9M | -79.2M |
| Ratios | ||||||
| ROE | 179.8% | - | -101.7% | -35.7% | -67.6% | -57.3% |
| ROA | 178.3% | 2.5% | -59.9% | -29.2% | -60.2% | -52.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Zura Bio Limited dividends
Zura Bio Limited has not paid dividends in the last 5 fiscal years.
Who owns Zura Bio Limited
- Insiders 18.83%
- Institutions 81.17%
- Public & others 0.00%
- Shares outstanding 96.3M
- Free float 45.6M
Zura Bio Limited company profile
- Company name
- Zura Bio Limited
- Ticker
- 94E.F
- ISIN
- KYG9TY5A1016
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 40
- Fiscal year end
- December
- Address
- 1489 W. Warm Springs Road, Henderson, NV, United States, 89014
- Phone
- 702 825 9872
- Website
- zurabio.com
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Zura Bio Limited management
7- Dr. Sandeep Chidambar Kulkarni M.D.Co-Founder, CEO & Director · born 1981
- Ms. Kimberly Ann Davis J.D.COO, Chief Legal Officer & Corporate Secretary · born 1968
- Dr. Kiran Nistala MBBS, Ph.D.Chief Medical Officer & Head of Development · born 1973
- Ms. Marlyn MathewVP of Finance & Accounting and Principal Financial & Accounting Officer · born 1984
- Dr. Gary Whale Ph.D.Chief Technology Officer · born 1974
- Ms. Theresa LowryChief Human Resources Officer · born 1974
- Mr. Muzammil MustufaChief Business Officer